Prophylactic effect of tixagevimab–cilgavimab on COVID-19 infection and death in Japanese patients with B cell lymphoma

被引：0
|
作者：
Hiro Tatetsu
Yusuke Higuchi
Takafumi Shichijo
Kazutaka Oda
Hirotomo Nakata
Jun-ichirou Yasunaga
Kisato Nosaka
Masao Matsuoka
机构：
[1] Kumamoto University School of Medicine,Department of Hematology, Rheumatology and Infectious Diseases
[2] Kumamoto University Hospital,Department of Pharmacy
[3] Kumamoto University Hospital,undefined
来源：
International Journal of Hematology | 2023年 / 118卷
关键词：
Tixagevimab–cilgavimab; B cell lymphoma patients; COVID-19; CAR-T;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：303 / 305
页数：2
相关论文
共 50 条
  • [1] Prophylactic effect of tixagevimab-cilgavimab on COVID-19 infection and death in Japanese patients with B cell lymphoma
    Tatetsu, Hiro
    Higuchi, Yusuke
    Shichijo, Takafumi
    Oda, Kazutaka
    Nakata, Hirotomo
    Yasunaga, Jun-Ichirou
    Nosaka, Kisato
    Matsuoka, Masao
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (02) : 303 - 305
  • [2] Observational study of COVID-19 prophylactic antibody (tixagevimab/cilgavimab) administration for multiple myeloma patients
    Lee, Yoojin
    Jo, Jae-Cheol
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S298 - S298
  • [3] Real-world effectiveness of prophylactic tixagevimab-cilgavimab monoclonal antibodies on incidence and severity of COVID-19 infection in patients with cancer
    Naser, Maryam
    Bhardwaj, Prarthna V.
    Warriach, Fatima Zahid
    Jadoon, Yamna
    Gupta, Kush
    Rastegar, Vida
    Loke, Chandravathi
    Malleshappa, Sudeep Kumar Siddappa
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] A case of prolonged COVID-19 treated with tixagevimab/cilgavimab
    Shimizu, Takahiro
    Shirasaki, Hiroki
    Okafuji, Kazuhiro
    Sawazaki, Aiko
    Iwabuchi, Tasuku
    Matubayashi, Ryo
    [J]. RESPIROLOGY CASE REPORTS, 2023, 11 (03):
  • [5] Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review
    Ustianowski, Andrew
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2022, 20 (12) : 1517 - 1527
  • [6] Belt and Suspenders: Vaccines and Tixagevimab/Cilgavimab for Prevention of COVID-19 in Immunocompromised Patients
    Kotton, Camille N.
    [J]. ANNALS OF INTERNAL MEDICINE, 2022, 175 (06) : 892 - +
  • [7] Clinical Efficacy and Safety of Tixagevimab and Cilgavimab (Evusheld) on Preventing COVID-19 in Patients with MS on B-Cell Depleters
    Conte, W. L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 67 - 67
  • [8] Tixagevimab/Cilgavimab does not prevent COVID-19 in patients with multiple sclerosis and related disorders on B-cell depleting therapies
    Conway, Sarah
    Gupta, Saumya
    Healy, Brian
    Chuang, Tzu-Ying
    Stazzone, Lynn
    Sullivan, John
    Polgar-Turcsanyi, Mariann
    Chitnis, Tanuja
    Houtchens, Maria
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 87
  • [9] Tixagevimab/Cilgavimab for Prevention of Covid-19 in Newly Transplanted Kidney Recipients
    El Chediak, A.
    Bruns, C.
    Simard, R.
    Spence, K.
    Forbes, R.
    Concepcion, B. P.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S661 - S662
  • [10] The effect of tixagevimab-cilgavimab on clinical outcomes in patients with COVID-19: A systematic review with meta-analysis
    Wang, Yong
    Zheng, Jun
    Zhu, Kongfu
    Xu, Chengshi
    Wang, Daping
    Hou, Mengzhuo
    [J]. JOURNAL OF INFECTION, 2023, 86 (01) : E15 - E17
12345